Breaking News

Teva Names President and CEO

By Kristin Brooks | January 9, 2014

Vigodman to take over generic giant

Erez Vigodman has been appointed president and chief executive officer of Teva Pharmaceutical Industries, effective February 11, 2014. Mr. Vigodman will succeed acting president and chief executive officer Eyal Desheh, who will return to his position as group executive vice president and chief financial officer. Mr. Vigodman is currently president and chief executive officer of Makhteshim Agan Industries (MAI), a global generic agrochemical company.
Mr. Vigodman has led MAI since 2010, returning the company to profitability through operations improvements and investing in organic growth. He also led the expansion of MAI into emerging markets across Asia and Latin America, and China. Prior to MAI, Mr. Vigodman served as president and chief executive officer of Strauss Group, a global food and beverages company, where he led collaborations with leading global companies including Danone and PepsiCo.
Dr. Phillip Frost, chairman of the board of directors, said, “I would like to welcome Erez to his new position as the CEO of Teva. As a member of the Teva Board since 2009, Erez has a deep understanding of the company and the industry in which it operates, putting him in a strong position to hit the ground running and deliver value for shareholders. I would like to thank Eyal for leading the company through an important time and maintaining focus on the execution of our strategy.”
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks